Evidence map›Paper›PMID 31991681›Full record

ArticleVaccines2020

Influenza Anti-Stalk Antibodies: Development of a New Method for the Evaluation of the Immune Responses to Universal Vaccine.

Alessandro Manenti, Agnieszka Katarzyna Maciola, Claudia Maria Trombetta, Otfried Kistner, Elisa Casa, Inesa Hyseni, Ilaria Razzano, Alessandro Torelli, Emanuele Montomoli

Open access · goldAbstract read
In one paragraph

Article in Vaccines, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.3field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Alessandro ManentiVisMederi Research s.r.l., 53100 Siena, Italy.
Agnieszka Katarzyna MaciolaVisMederi Research s.r.l., 53100 Siena, Italy.
Claudia Maria TrombettaDepartment of Molecular and Developmental Medicine, University of Siena, 53100 Siena, Italy.
Otfried KistnerVisMederi s.r.l., 53100 Siena, Italy.
Elisa CasaVisMederi Research s.r.l., 53100 Siena, Italy.
Inesa HyseniVisMederi Research s.r.l., 53100 Siena, Italy.
Ilaria RazzanoVisMederi Research s.r.l., 53100 Siena, Italy.
Alessandro TorelliVisMederi Research s.r.l., 53100 Siena, Italy.
Emanuele MontomoliVisMederi Research s.r.l., 53100 Siena, Italy.
VisMederi Research · ITUniversity of Siena · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Growing interest in universal influenza vaccines and novel administration routes has led to the development of alternative serological assays that are able to detect antibodies against conserved epitopes. We present a competitive ELISA method that is able to accurately determine the ratio of serum immunoglobulin G directed against the different domains of the hemagglutinin, the head and the stalk. Human serum samples were treated with two variants of the hemagglutinin protein from the A/California/7/2009 influenza virus. The signals detected were assigned to different groups of antibodies and presented as a ratio between head and stalk domains. A subset of selected sera was also tested by hemagglutination inhibition, single radial hemolysis, microneutralization, and enzyme-linked lectin assays. Pre-vaccination samples from adults showed a quite high presence of anti-stalk antibodies, and the results were substantially in line with those of the classical serological assays. By contrast, pre-vaccination samples from children did not present anti-stalk antibodies, and the majority of the anti-hemagglutinin antibodies that were detected after vaccination were directed against the head domain. The presented approach, when supported by further assays, can be used to assess the presence of specific anti-stalk antibodies and the potential boost of broadly protective antibodies, especially in the case of novel universal influenza vaccine approaches.

Indexed as

competitive ELISAHA2-antibodyhemagglutininstalk domainuniversal influenza vaccine

Identifiers

PMID31991681
PMCPMC7158664
OpenAlexW3002475016

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.